<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031754</url>
  </required_header>
  <id_info>
    <org_study_id>223047/Z/21/Z</org_study_id>
    <nct_id>NCT05031754</nct_id>
  </id_info>
  <brief_title>Assessing SleeP IN Infants With Atopic Dermatitis by Longitudinal Evaluation</brief_title>
  <acronym>SPINDLE</acronym>
  <official_title>Assessing SleeP IN Infants With Early-onset Atopic Dermatitis by Longitudinal Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Service Executive, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Cork</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SPINDLE study will examine sleep in infants with atopic dermatitis by serial assessment&#xD;
      over the first year of life, in comparison to infants without atopic dermatitis. Sleep will&#xD;
      be assessed using electroencephalography, actigraphy, and sleep questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants will be recruited at 6 to 8 months and followed up until 18 months of age. Sleep&#xD;
      electroencephalography will be performed at 6 to 8 months. Sleep actigraphy will be performed&#xD;
      at 6 to 8 months and 12 months. Infant sleep questionnaires will be completed on a monthly&#xD;
      basis, and parental sleep questionnaires will be completed at 6 to 8 months, 9 to 10 months,&#xD;
      and 12 months. A neurodevelopmental assessment will be performed at 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Altered macrostructure of sleep from 6 to 12 months measured with parental sleep diaries</measure>
    <time_frame>6 months to 12 months</time_frame>
    <description>Measured as decreased sleep efficiency and increased night time awakenings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Altered macrostructure of sleep at 6 and 12 months measured by nocturnal actigraphy</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Measured as sensor-detected movement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Altered microstructure of sleep at six-eight months using electroencephalography to measure sleep spindle power in rapid eye movement and non-rapid eye movement stages</measure>
    <time_frame>6-8 months</time_frame>
    <description>Measured as sleep spindle power and power in rapid eye movement (REM) and non-rapid eye movement (NREM) sleep stages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental sleep quality and quality of life measured using the Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>6 months to 12 months</time_frame>
    <description>Measured using standardized questionnaire (PSQI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of atopic dermatitis in cases as assessed using SCORAD (SCORing Atopic Dermatitis)</measure>
    <time_frame>6 months to 12 months</time_frame>
    <description>Measured using standardized clinical assessment score (SCORAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of atopic dermatitis in cases as assessed using the Eczema Area and Severity Index (EASI)</measure>
    <time_frame>6 months to 12 months</time_frame>
    <description>Measured using standardized clinical assessment score (EASI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of atopic dermatitis in cases as assessed using Investigator's Global Assessment scale (IGA)</measure>
    <time_frame>6 months to 12 months</time_frame>
    <description>Measured using standardized clinical assessment scores (IGA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurodevelopmental assessment</measure>
    <time_frame>At 18 months of age (one-off assessment)</time_frame>
    <description>Measured using novel touchscreen app ('Cognitot')</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Infants with atopic dermatitis</arm_group_label>
    <description>Infants with atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants without atopic dermatitis</arm_group_label>
    <description>Infants without atopic dermatitis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Inflammatory cytokine analysis is being performed by tape stripping.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infants under six months of age diagnosed with moderate to severe AD are eligible for the&#xD;
        study. Healthy control infants, matched in age, will be recruited for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Moderate to severe atopic dermatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Premature birth (under 37 weeks gestation)&#xD;
&#xD;
          -  Severe medical condition (such as epidermolysis bullosa or ichthyosis) at time of&#xD;
             enrolment that would complicate assessment for AD or preclude the use of&#xD;
             investigational tools, or other major health problems (especially genetic or&#xD;
             metabolic) that would have implications for neurodevelopment&#xD;
&#xD;
          -  Any medical condition requiring the using of sedating medications (eg antihistamines)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geraldine Boylan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INFANT, University College Cork</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathal O'Connor, MD</last_name>
    <phone>+353877919176</phone>
    <email>cathal.oconnor@ucc.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>INFANT</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathal O'Connor, MD</last_name>
      <phone>0877919176</phone>
      <email>cathal.oconnor@ucc.ie</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

